Wednesday 25th July 2012
|Text too small?|
Comvita, which makes products based the virtues of honey, will ask shareholders to approve a deeper pool of fees for directors to draw on at tomorrow's annual meeting.
The Te Puke-based company wants to raise the maximum aggregate fees payable to $400,000 from the current $300,000, it said in its notice of meeting. If Comvita gets sign-off on the increase, it will raise fees over the next two years, and will also cover the addition of a sixth director if need be.
"The proposed additional directors' remuneration above also allows some 'headroom' to cover situations where the board may decide to make a payment to a director for assisting the company in duties significantly over and above the normal directors' duties," the company said.
"Such additional may include capital raising, acquisitions, dealing with a takeover of Comvita, or assisting on special products undertaken by the executive team," it said.
Last month, Comvita issued shareholding beekeepers with bonus stock after an on-market buyback, rewarding its most loyal suppliers.
The company fought off a hostile takeover bid by Cerebos Greggs, and went on to post a record profit on fatter sales.
The shares were unchanged at $3.20 in trading today, having surged by a third this year.
The stock is rated a 'hold' according to the one analyst recommendation compiled by Reuters, with a target price of $2.91.
No comments yet
Comvita may not increase earnings in 2014 as higher honey prices bite, Craigs says
Comvita turned to a loss in first half, remains confident of increasing annual profit
Nasdaq-listed Derma Sciences takes 7.3 percent stake in Comvita in discounted placement
Comvita FY profit falls 10 percent , beating guidance, on honey shortage, rising costs
Comvita flags 15 percent fall in FY profit as expensive honey, supply shortages prompt downgrade
Comvita buys Aussie groves to expand olive extract output
Comvita first-half earnings fall 7.4% amid short supply
Comvita buys Whanganui-based Kiwi Honey for undisclosed sum
Comvita hits 5-yr high on early results from diabetes trial
Comvita's net profit surges to a record, dividend jumps